Physician profile
Hung V Ong
NPI 1407842149
$4,360.35
in general payments reported to CMS, 2019-2025
27 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 77% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $456 · 2021: $194 · 2022: $692 · 2023: $1,041 · 2024: $835 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,018.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,018.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,486.82 | 2019-2025 | |
| Pfizer INC. | $683.96 | 2019-2025 | |
| Genzyme Corporation | $369.63 | 2021-2025 | |
| Incyte Corporation | $241.87 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $229.39 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2022 | |
| Covidien LP | $124.06 | 2019 | |
| Amgen INC. | $123.16 | 2023-2025 | Otezla, Otezla |
| Gilead Sciences, INC. | $122.79 | 2023 | Vemlidy |
| Allergan, INC. | $119.53 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $119.06 | 2022-2024 | |
| Endogastric Solutions, INC | $116.31 | 2019 | |
| Galderma Laboratories, L.P. | $80.97 | 2024-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $60.47 | 2025 | Libtayo |
| Leo Pharma INC. | $58.31 | 2022-2023 | Adbry |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $48.65 | 2024 | Bimzelx |
| Solta Medical, A Division of Bausch Health US, LLC | $41.91 | 2025 | Clear+Brilliant |
| Biofrontera INC. | $33.38 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| E.R. Squibb & Sons, L.L.C. | $30.51 | 2024 | Sotyktu |
| Revance Therapeutics, INC. | $28.86 | 2024-2025 | Daxxify |
| Arcutis Biotherapeutics, INC. | $23.75 | 2024 | Zoryve |
| Lilly USA, LLC | $22.17 | 2024 | Zepbound, Taltz |
| Janssen Biotech, INC. | $19.50 | 2025 | Tremfya |
| Dermavant Sciences, INC. | $14.29 | 2024 | Vtama |
| Misonix INC | $13.69 | 2021 | |
| Strata Skin Sciences, INC. | $13.62 | 2025 | Xtrac |
| Bard Peripheral Vascular, INC. | $8.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Ong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.